Biolexis management participated and presented pre-clinical data on CDK9 inhibitor at the AACR (American Association of Cancer Research) Annual Meeting on April 8-13, 2022, Ernest N. Morial Convention Center New Orleans, Louisiana.
B137 / 13 – Orally available, CDK9 selective, small molecule inhibitors shows promise in n-Myc-driven neuroendocrine prostate cancers (NEPC)
Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2.
October 26, 2023 Biolexis Therapeutics, a clinical-stage AI-enabled drug discovery company, today announced the launch of Metabolexis, a new pipeline company developing three targeted oral small molecules for the treatment of Obesity and Type 2 Diabetes, with the...
November 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E....
October 11-15, 2023 Biolexis Therapeutics Scientific Team participates and present their IND stage small molecule CDK9 inhibitor program for Pancreatic Cancers indications at The “AACR-NCI-EORTC” International Conference on Molecular Targets and Cancer...